Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue

• US 7,840,262 B2
• Filed: 03/10/2004
• Issued: 11/23/2010
• Est. Priority Date: 03/10/2003
• Status: Active Grant

• Current Assignee: Impulse Dynamics NV
• Original Assignee: Impulse Dynamics NV
• Inventors: Rousso, Benny, Sabbah, Hani N., Mika, Yuval, Haddad, Walid
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Lee; Yun Haeng
• Application Number:
  US10/549,216
• Publication Number:
  US 20070027487A1
• Time in Patent Office: 2,449 Days
• Field of Search: 607/2, 607/3
• US Class Current: 607/2
• CPC Class Codes: A61N 1/0587 Epicardial electrode systems; Endocardial electrodes piercing the pericardium
• CPC Class Codes: A61N 1/326 for promoting growth of cells, e.g. bone cells
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/36557 controlled by chemical substances in blood
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Method and apparatus (120) for modifying gene expression in cardiac muscle cells (110), by the application of electric fields.

Claims

1. A method for improving heart function comprising electrically modifying the expression in heart tissue of genes that effect cardiovascular system function using an electric field to intentionally both modify the expression and modify a cardiac function, wherein the field is applied to diseased cardiac cells in a heart in which they formed.

2. The method of claim 1, wherein said field is applied by an implantable device adapted to apply a non-excitatory field to a heart in a manner which acutely affects a functioning of said heart, characterized in that the device is adapted to take an effect on gene expression into account in its functioning.

3. The method of claim 2, wherein said device includes a feedback control loop which modifies an application of non-excitatory field in response to an indication of a gene expression effect of a previous application of a non-excitatory field.

4. The method of claim 3, including a watchdog which stops or modifies application of an electrical signal to a heart responsive to an effect of such application on gene expression in the heart.

5. The method of claim 1, wherein said field is applied by an implantable device configured to deliver non-excitatory or non-excitatory and excitatory signals to heart tissue that will modify gene expression of muscle cells in the heart tissue in a way to improve the cardiac function of the cells.

6. The method of claim 1, wherein said field is applied by an implantable device configured to deliver cardiac contractility modulation signals including a non-excitatory contractility modulating component to heart tissue that will modify the expression of BNP and ANP in the heart tissue for treatment of heart failure.

7. The method of claim 1, wherein said field is applied by an implantable device configured to deliver cardiac contractility modulation signals including a non-excitatory contractility modulating component to heart tissue that will normalize the expression of alfa myosin heavy chain aMHC in the heart tissue for treatment of heart failure.

8. The method of claim 1, wherein said field is applied by an implantable device configured to deliver cardiac contractility modulation signals including a non-excitatory contractility modulating component that will modify the expression of basic fibroblast growth factor (bFGF) in the heart tissue for treatment of heart failure.

9. The method of claim 1, wherein the electric field includes an excitatory component.

10. The method of claim 1, wherein the field reduces mRNA gene expression of BNP, ANP, or both BNP and ANP.

11. A method according to claim 10, comprising monitoring said ANP and/or BNP in blood serum.

12. A method according to claim 10, comprising applying said electric field for fewer than 10% of beats in a day.

13. A method according to claim 10, comprising applying said electric field for between 10% and 50% of beats in a day.

14. The method of claim 1, wherein the field modifies mRNA gene expression for bFGF to above normal level.

15. The method of claim 1, wherein the field normalizes nRNA gene expression for aMHC.

16. The method of claim 1, wherein the field reduces mRNA gene expression of BNP, ANP, or both BNP and ANP.

17. The method of claim 1, wherein the field includes a non-excitatory component which causes at least part of said modifying the expression.

18. The method of claim 1, wherein the field includes a non-excitatory component which causes at least part of said modifying the function.

19. A method for treating heart failure comprising electrically modifying the expression in heart tissue of genes that effect cardiovascular system function using an electric field to intentionally both modify the expression and modify a cardiac function, wherein the field is applied to diseased cardiac cells in a heart in which they formed.

20. The method of claim 19, wherein the heart failure is congestive heart failure.

21. The method of claim 19, wherein the electric field includes an excitatory component.

22. The method of claim 19, wherein the field includes a non-excitatory component which causes at least part of said modifying the expression.

23. The method of claim 19, wherein the field includes a non-excitatory component which causes at least part of said modifying the function.

24. A method of treating a patient with a cardiac related disease, comprising:

determining a desired target gene expression profile in cardiac tissue; and

applying a non-excitatory signal to the cardiac tissue to modify the gene expression in accordance with the desired target gene expression profile.

25. A method according to claim 24, comprising stopping said applying when said target is reached.

26. A method according to claim 24, wherein said applying comprises applying for at least four hours.

27. A method for improving heart function comprising electrically modifying the expression in heart tissue of genes that effect cardiovascular system function using an electric field that both modifies the expression over a long term and acutely improves cell function of said heart, wherein the non-excitatory signal is applied to diseased cardiac cells in a heart in which they formed.

28. The method of claim 27, wherein the field includes a non-excitatory component which causes at least part of said modifying the expression.

29. The method of claim 27, wherein the field includes a non-excitatory component which causes at least part of said modifying the function.

30. A method of treating a patient with heart failure, comprising:

determining a desired target gene expression profile in cardiac tissue, said profile associated with improvement in cardiac failure; and

applying a non-excitatory signal to the cardiac tissue to modify the gene expression in accordance with the desired target gene expression profile, wherein the non-excitatory signal is applied to diseased cardiac cells in a heart in which they formed.

31. The method of claim 30, wherein applying comprises applying said signal at a voltage of between 3 and 15 volts.

32. The method of claim 31, wherein applying comprises applying said signal, at a delay of between 20 and 100 milliseconds from a local activation.

33. The method of claim 32, wherein applying comprises applying said signal, with a duration of between 10 and 50 milliseconds.

34. The method of claim 33, wherein applying comprises applying said signal to the right side of a ventricular septum.

35. The method of claim 34, wherein applying comprises applying said signal for between 1 and 6 hours a day using an implantable stimulator.

36. The method of claim 32, wherein applying comprises applying said signal, with a duration of between 20 and 40 milliseconds.

37. The method of claim 31, wherein applying comprises applying said signal, at a delay of between 20 and 100 milliseconds from a pacing.

38. The method of claim 30, wherein applying comprises applying said signal for between 1 and 6 hours during a period of a day including at least one break period in said applying.

39. A method of treating a patient with a diseased heart, comprising:

(a) determining a desired target gene expression profile in in-vivo cardiac tissue of a diseased heart, said profile associated with improvement in cardiac function; and

(b) applying an electrical signal to diseased cardiac cells formed in the diseased heart to modify the gene expression in accordance with the desired target gene expression profile.

40. A method according to claim 39, wherein said modification in expression lasts after said signal is stopped.

41. A method according to claim 39, wherein a modification in expression lasts at least one week after said signal is stopped.

42. A method according to claim 39, wherein said improvement in cardiac function comprises a reversal in progression of heart failure.

43. A method according to claim 39, wherein said modification in expression comprises a normalization of said profile.

44. A method according to claim 39, wherein said improvement in cardiac function comprises an improvement in contractility.

45. A method according to claim 39, wherein said improvement in cardiac function comprises a reduction in arrhythmia.

46. A method according to claim 39, wherein said applying also has an immediate beneficial effect on cardiac function.

47. A method according to claim 39, wherein said applying does not have an immediate beneficial effect on cardiac function.

48. A method according to claim 39, wherein said signal includes a non-excitatory electrical component which provides at least part of said modifying.

49. A method according to claim 39, comprising closing a loop on said applying using an implantable device.

50. A method according to claim 39, wherein said applying comprises applying after identifying a protocol of applying expected to provide a modification in accordance with said desired gene expression profile.

51. A method according to claim 39, comprising repeating said applying to maintain said modifying of said gene expression profile.

52. A method according to claim 39, comprising repeating said applying to achieve said desired gene expression profile.